← All SBIR agencies · Department of Defense · Topic search

AF203-DCSO1

Department of Defense · 96 awards from 2021 to 2025 · 82 distinct firms

Awards in this topic include: “High Mach Airbreathing Target (HMAT)” · “Parraid Outsourcing Workload (O.W.L) Linux Power and Data Hub” · “NASIC GXK STRATFI Proposal - OCR enabled intelligence”

This is a Direct-to-Phase-II topic. There is no Phase I stage — all 96 awards are Phase II, so there is no Phase I award size or conversion rate to report.

What awards in this topic are actually worth

Median Phase II award $749,921

Middle half fell between $748,742 and $750,000 (96 Phase II awards). The largest was $30,000,000 — the upper tail here includes multi-year instruments such as STRATFI and Sequential Phase II, which run to eight figures and are not comparable to a standard Phase II.

Award values are as reported by the agency to sbir.gov. For contract awards that is the value of the award, which for multi-year instruments covers several years rather than a single year's funding.

Who wins here

Distinct firms that have won 82

Across 96 awards.

Share held by the top 3 firms 8.3%

The single biggest winner, AEROCINE VENTURES, INC., holds 4.2% (4 of 96). That is a wide-open topic — no firm has a lock on it.

First-time winners at Department of Defense 18

of 82 firms had no prior Department of Defense award before winning here (64 were returning winners). This is the closest honest answer to “can a newcomer win in this topic”.

Most awards in this topic

FirmAwardsShare
AEROCINE VENTURES, INC.4 4.2%
FGC Plasma Solutions, Inc.2 2.1%
PARRAID LLC2 2.1%
VANNEVAR LABS INC2 2.1%
AMERICAN LITHIUM ENERGY CORP.2 2.1%

Firms are counted by federal UEI where available. sbir.gov has backfilled UEIs to 99.5% coverage for 2025 awards; a company that re-registered may appear more than once in older years, which would understate concentration slightly.

Get an email when new data drops

Quarterly-ish, and only when something's actually new — a new SBA report year, a new stat, a dataset update. The weekly refresh alone never triggers an email. No account, one-click unsubscribe, and every number on this page stays free and open either way.

Sources and caveats (the honest part)

Sourced vs computed: Phase I/II selection rates (applications → awards) come from the SBA's SBIR/STTR Annual Report — FY2022 is the latest published edition, and SBA itself calls the rates estimates because proposal cohorts span fiscal years. Phase I→II conversion and first-timer shares are computed by us from sbir.gov's public award records. Linked by firm + agency + topic code where topic codes carry (suffix-tolerant for DOE's phase renumbering), with a title-similarity fallback elsewhere. 70% of links match on topic, 30% on title; each pair's match_tier is in the downloadable CSV, so you can recompute under stricter rules. Firms are identified by federal UEI where available (99.5% of 2025 awards, down to 54% for 2001), with a normalized-name fallback for older records.

Fast-track and Direct-to-Phase-II: no agency publishes a fast-track flag, so we derive it — HHS/NIH: a Phase I record carrying a Phase II activity code (R44/R42/U44) plus its linked Phase II; NSF: the 2024 Fast-Track pilot solicitation (NSF 24-582). Where fast-track exists, conversion is shown both organic (fast-tracks excluded) and all-inclusive, because a fast-track Phase II was committed at award time, not competed. DoD's Direct-to-Phase-II share is different in kind: there is no marker at all, so our number is an inference (Phase IIs with no same-firm DoD Phase I in the prior 3 years), always labeled an estimate and kept visually separate from measured stats.

What nobody publishes: per-topic application counts are published by no one — not the agencies, and not the $500–$42,000-a-year intelligence platforms either; the data simply isn't public. Any per-topic number on this site is award-side only (who won, how often winners repeat), never your odds of selection.

Sources: sbir.gov award data · SBA FY22 Annual Report. Free to use; verify anything critical against the originals.